5244122026-01-012026-03-315244122026-03-315244122025-03-315244122025-04-012026-03-315244122026-01-012026-03-31in-capmkt:OtherExpenses1Member5244122025-04-012026-03-31in-capmkt:OtherExpenses1Member5244122026-03-31OtherCurrentFinancialAssetsDomain15244122026-03-31OtherCurrentFinancialLiabilitiesDomain15244122026-03-31OtherCurrentFinancialLiabilitiesDomain25244122026-01-012026-03-31RelatedPartyTransactionDomain15244122025-12-31RelatedPartyTransactionDomain15244122026-03-31RelatedPartyTransactionDomain15244122026-01-012026-03-31RelatedPartyTransactionDomain25244122025-12-31RelatedPartyTransactionDomain25244122026-03-31RelatedPartyTransactionDomain25244122026-01-012026-03-31AuditorDomain15244122026-03-31Statement15244122026-01-012026-03-31Statement15244122026-03-31StatementDynamic1I1Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares524412AAREYDRUGSNOTLISTEDINE198H01019Aarey Drugs & Pharmaceuticals LimitedMain BoardEquity2025-04-012026-03-312026-05-302026-05-29INRLakhsQuarterlyFourth quarterSingle segmentDRUGS AND PHARMACEUTICALS2026-05-3017:00:002026-05-3019:20:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2026-05-29http://www.aareydrugs.com/true1falseNot Applicable2026-01-012026-03-31AuditedStandalone1894724000-4294000189043000017929600000961000289700017847000846400054500000187762900012801000012801000-27730000-2773000015574000000015574000015574000284543000100.550.55000.550.552025-04-012026-03-31AuditedStandalone47226900006097100047836610004505629000039441000759000050018000285300009831100047295190005414200005414200015925000-1459000144660000396760000000396760000396760002845430001001.391.39001.391.39other54500000other9831100025778400000000002115000006411000085260000034304400041536200001296547000139860000206045000697483000221406100026294230002972467000284543000121968900015042320001504232000974000097400000772900017469000489876000081589000081589000010788100014136470002119400015925000145076600014682350002972467000other697483000other financial liabilities10000other current liabilities1078710005001800039441000380890000-243300000-1387360000-2095170000112330000285300000-60620000-37000000000000252648000063174000117316000000159240000101392000000000000124108000000000000000000000000-124108000000000000000002196900021969000-7470000-7470001473300013986000Aarey Drugs & Pharmaceuticals Limited******Enam Organics India Ltd******Entity in which Director has interestLoanApproved12665400016733900040685000Loan00Aarey Drugs & Pharmaceuticals Limited******Worth Investment & Trading Co Ltd******Entity in which Director has interestLoanApproved7770200026788000104470000Loan00204356000AuditedtrueMotilal & Associates LLPtrue2026-08-31Preferential Issues2025-05-23797500002026-03-31falsefalseMira GhataliaChief Financial OfficerMumbai2026-05-30The Company as a part of its financial strategy proposes to offer, issue and allot Convertible Warrants to its Promoter/Non Promoter/Promoter group member on preferential basis, for infusing additional funds in the Company which may be employed in the business of the Company and/or may be used to augment the funding needs for re-structuring/settlement of liabilities/debts and/or such other appropriate arrangements and/or understanding with Bankers and/or other Creditors and/or investment in technology and/or for general corporate purposes which shall enhance the business of the Company and for any other purpose as may be decided and approved by the Board NA3190000000797500000The Company allotted 50,00,000 Convertible Warrants on May 23, 2025 at an issue price of Rs. 63.80 per warrant aggregating to Rs.3,190.00 Lakhs. In accordance with SEBI (ICDR) Regulations, 25% of the consideration amounting to Rs.797.50 Lakhs was received at the time of allotment and the same has been utilized for the stated objects. The balance 75% consideration amounting to Rs.2,392.50 Lakhs is receivable upon exercise/conversion of warrants within the prescribed period and therefore has not been raised as on March 31, 2026.